首页> 美国卫生研究院文献>Internal Medicine >Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report
【2h】

Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report

机译:组织学转化为肺腺癌的大细胞神经内分泌癌其携带EGFR突变:尸检病例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We herein report a 58-year-old Japanese woman who survived 14 years after surgery for lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) exon 19 deletion. She developed recurrence, for which she underwent multimodal therapy, including EGFR-tyrosine kinase inhibitor (TKI) administration. She ultimately died from a rapidly progressive right lung tumor that was resistant to EGFR-TKI. According to the autopsy findings, she had combined large-cell neuroendocrine carcinoma (LCNEC) and adenocarcinoma in the right lung, which retained an EGFR exon 19 deletion in both components. Therefore, the histological transformation to LCNEC can be a mechanism of acquired EGFR-TKI resistance.
机译:我们在此报告了一名58岁的日本妇女,她因携带表皮生长因子受体(EGFR)外显子19缺失的肺腺癌手术后存活了14年。她发展为复发,为此她接受了多种模式的治疗,包括EGFR-酪氨酸激酶抑制剂(TKI)的给药。她最终死于对EGFR-TKI有抵抗力的快速进展的右肺肿瘤。根据尸检结果,她在右肺合并了大细胞神经内分泌癌(LCNEC)和腺癌,这两个部位均保留了EGFR外显子19缺失。因此,向LCNEC的组织学转化可以是获得性EGFR-TKI抗性的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号